MedTrace Logo

Taste and Local Tolerance Study of NLA Nasal Spray in Patients With Allergic Rhinitis

NCT00533637 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2008-03-05

No results posted yet for this study

Summary

Evaluation of NLA Nasal Spray with regard to taste perversion and local tolerance

Conditions

  • Allergic Rhinitis

Interventions

DRUG

Cetirizine dihydrochloride (10 mg/ml) liposomal formulation

2x110μL in each nostril twice daily for 7 days

DRUG

Cetirizine dihydrochloride (10 mg/ml) buffer solution

2x110μL in each nostril, as a single dose

DRUG

Placebo

Citrate buffer with preservatives

Sponsors & Collaborators

  • Biolipox AB

    lead INDUSTRY

Principal Investigators

  • Lennart Greiff, MD, PhD · University of Lund

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Completion
2007-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00533637 on ClinicalTrials.gov